Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2022 on October 20, 2022

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) will host a conference call (in English) for investors, analysts and media on Thursday, October 20, 2022, at 15:00 CET / 9:00 am ET. Alligator will publish the company's interim report on Thursday, October 20, 2022, at 8:00 CET / 2:00 am ET.

CEO Søren Bregenholt and CFO Marie Svensson will present the interim report for the period January – September 2022 followed by a Q&A session.

The conference call will be broadcast live on the web and can be accessed via the link:

https://financialhearings.com/event/44199

The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on October 17, 2022.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as